An article about Mammatyper test was published in november 2016 in the journal Medical Market. The text presented the clinical utility of the test stating that it generates a quick response, automation and objective, claiming that molecular biology method is superior to immunohistochemistry.

„According to the speciality articles, immunohistochemistry has its limits and often generates either a false pozitive or false negative results which will complete at the wrong choice of therapy. The molecular biology techniques, that are bases assay Mammatyper, it is more sensitive compared to immunohistochemistry and quantitatice analyzing the expression level of the gene enconding the 4 markers [ERBB2 (HER2), ESR1 (ER), PGR (PR) și )MKI67 (Ki67)] esentials for subtyping”, said the authors.